Company Information

Patent

Status of our key patents of core pipeline is as follows.

OBP-301 (Telomelysin®)
Title of Invention Oncolytic virus replicating selectively in tumor cells
Disease Area Various types of cancers
Patent Owner Oncolys BioPharma Inc. and Kansai TLO Co., Ltd.
Rights of Oncolys BioPharma Owner of patents (*Note)
Country / Patent Number Japan:3867968
USA:8163892
Europe:1553178
Australia:2003281310
Canada:2491907
China:ZL03816064.1
Hong Kong:1082958
Republic of Korea:10-0947194
New Zealand:537631
singapore:109.276
South Africa:2005/0047
status Patents concerning drug substance issued in 11 countries including Japan and the U.S.A.
Note: Japan patent is owned jointly by Oncolys BioPharma Inc. and Kansai TLO Co., Ltd. and patents issued in other than Japan solely owned by Oncolys BioPharma Inc.
OBP-601 (Censavudine)
Title of Invention Ainti-viral nucreoside analog and methods for treating viral infections, especially HIV infections
Disease Area HIV
Patent Owner Yale University, etc.
Rights of Oncolys BioPharma Worldwide exclusive license
Country / Patent Number Japan:4980059
USA:7589078, 8193165, 9126971
Europe:Pending
Australia:2004260630
Canada:2514466
China:ZL200480010529.6
Hong Kong:1087341
Russian Federation:12844
Israel:169944
Republic of Korea:10-1228503
Mexico:281038
New Zealand:541594
Poland:219609
Singapore:115981
Status Patents concerning drug substance issued in 13 countries including Japan and the U.S.A.
OBP-801
Title of Invention Novel depsipeptide compound
Disease Area Various types of cancers
Patent Owner Astellas Pharma Inc.
Rights of Oncolys BioPharma Worldwide exclusive license
Country / Patent Number Japan:3554707
USA:6670326, 7098024
Ireland:1142905
United Kingdom:1142905
Italy:1142905
Austria:1142905
Netherlands:1142905
Greece:1142905
Switzerland:1142905
Sweden:1142905
Spain:1142905
Denmark:1142905
Germany:60029084
Finland:1142905
France:1142905
Belgium:1142905
Portugal:1142905
Canada:2356845
China:ZL00802510.X
Republic of Korea:10-0611265
Status Patents concerning drug substance issued in 20 countries including Japan, U.S.A., and Europe
OBP-401 (TelomeScan®)
Title of Invention Telomelysin / GFP-expressing recombinant virus
Disease Area Detection of cancer and inflammatory diseases
Patent Owner Oncolys BioPharma Inc.
Rights of Oncolys BioPharma Owner of Patents
Country / Patent Number Japan:5006045
United Kingdom:2311499
France:2311499
Germany:2311499
Italy:2311499
Netherlands:2311499
Russian Federation:11880
India:246555
New Zealand:554799
Singapore:130465
Status Patents concerning substance issued in 10 countries including Japan and Europe and also protected by patents for OBP-301 (Telomelysin®).
OBP-1101 (TelomeScan F35)
Title of Invention Conditionally replication-competent adenovirus
Disease Area Detection of cancer
Patent Owner National Institute of Biomedical Innovation
Rights of Oncolys BioPharma Worldwide exclusive license
Country / Patent Number Japan:5812361, 5971599
USA:9624476
Europe:Pending
China:103857795
Hong Kong:Pending
Republic of Korea:Pending
Australia:2012298013
Canada:Pending
Russian:Pending
India:Pending
Singapore:11201400139
New Zealand:622585
Status Patents concerning substance issued in 6 countries including Japan and also protected by patents for OBP-301 (Telomelysin®) and OBP-401 (TelomeScan®)
pagetop